Extranodal NK/T-cell lymphoma: Updates in biology and management strategies

Best Pract Res Clin Haematol. 2018 Sep;31(3):315-321. doi: 10.1016/j.beha.2018.07.002. Epub 2018 Jul 3.

Abstract

Extranodal NK/T-cell lymphoma, nasal type (ENKL), is a rare lymphoma subtype of peripheral T/NK-cell lymphoma that is very common in East Asia and Latin America. Two-thirds of patients have localized disease in the nasal cavity or adjacent sites. Large retrospective studies have revealed the clinicopathologic features of ENKL patients, identified risk factors for short survival time, and developed prognostic models. Next-generation sequencing studies have provided a comprehensive list of recurrent mutations in ENKL. Since the early 2000s, disease-specific therapeutic approaches have been developed, and the standard of care for ENKL has markedly changed. Non-anthracycline-containing chemotherapy with or without radiotherapy is the current standard approach for ENKL treatment. Emerging therapies, including the use of immune checkpoint inhibitors, are being investigated.

Keywords: Chemotherapy; Gene mutations; NK/T-cell lymphoma; Radiotherapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Chemoradiotherapy / methods*
  • Disease-Free Survival
  • High-Throughput Nucleotide Sequencing*
  • Humans
  • Lymphoma, Extranodal NK-T-Cell* / genetics
  • Lymphoma, Extranodal NK-T-Cell* / mortality
  • Lymphoma, Extranodal NK-T-Cell* / pathology
  • Lymphoma, Extranodal NK-T-Cell* / therapy